UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade
UBS has upgraded Viatris Inc. (VTRS) to a "buy" rating, citing the company's improved capital allocation strategies and anticipated increase in profits. This upgrade suggests a positive outlook for Viatris's financial performance and strategic direction.
David Einhorn: These Top 10 Positions Make Up 75.85% Of His Portfolio (Analysis)
David Einhorn's top 10 positions comprise 75.85% of his current portfolio, with Green Brick Partners Inc. (GRBK) being the largest at 27.51%. The analysis details his holdings, noting significant increases in CNH Industrial NV and Peloton Interactive Inc., and substantial reductions in HP Inc. and Kyndryl Holdings Inc., reflecting varying levels of conviction across different sectors.
DFAT: Active Small Value ETF Beating Passive Competitors (NYSEARCA:DFAT)
The Dimensional US Targeted Value ETF (DFAT) is an actively managed fund focusing on small-cap value and profitability, holding 1,313 stocks with a 1.40% yield and 0.28% expense ratio. DFAT is highly diversified but concentrated in financials (29.1% of assets) and has generally outperformed its benchmark and peers since June 2021. While a strong small-cap value option, the article suggests AVUV offers higher returns, better liquidity, and slightly lower fees.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is a smart beta ETF that equally weights stocks in the health care sector of the S&P 500 Index. With over $770.19 million in assets and an expense ratio of 0.40%, RSPH offers diversified exposure to the healthcare sector, with top holdings including Moderna Inc, Viatris Inc, and Gilead Sciences Inc. While it has shown a 3.08% return and 8.87% year-to-date performance, investors seeking lower costs or different weighting strategies might consider alternatives like Vanguard Health Care ETF (VHT) or State Street Health Care Select Sector SPDR ETF (XLV).
Shareholders of Viatris Inc. Should Contact Levi & Korsinsky Bef
Levi & Korsinsky, LLP has announced a class action securities lawsuit against Viatris Inc. (NASDAQ: VTRS), advising investors who suffered losses between August 8, 2024, and February 26, 2025, to contact them by June 3, 2025. The lawsuit alleges that Viatris misrepresented the impact of a warning letter from the FDA concerning its Indore, India facility, leading to a significant stock price drop following disappointing 2025 guidance. Affected shareholders may be entitled to compensation without out-of-pocket costs.
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline
Viatris (VTRS) is projected to report a decline in both earnings and revenues for the fourth quarter ended December 2025, with an expected EPS of $0.52 per share and revenues of $3.52 billion. The consensus EPS estimate has seen a slight upward revision recently. Despite a strong track record of beating EPS estimates in the past, Viatris's current Zacks Earnings ESP of 0% and Zacks Rank #3 suggest it's difficult to conclusively predict an earnings beat this quarter.
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline
Viatris (VTRS) is projected to report a decline in both earnings and revenues for the fourth quarter of 2025. The company's upcoming earnings report on February 26 could impact its stock price depending on whether the actual results beat or miss expectations. Despite the consensus EPS estimate being revised slightly higher, Viatris's Earnings ESP of 0% and a Zacks Rank of #3 make it difficult to conclusively predict an earnings beat.
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline
Viatris (VTRS) is projected to report a decline in both earnings and revenues for the fourth quarter of 2025. The company is expected to post quarterly earnings of $0.52 per share, a 3.7% year-over-year decrease, on revenues of $3.52 billion, down 0.3%. Despite a slight upward revision in the consensus EPS estimate, Viatris's current Zacks Rank of #3 and a 0% Earnings ESP make it difficult to conclusively predict an earnings beat.
EyePoint appoints Michael Campbell as chief commercial officer
EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer to lead the commercial strategy for its investigational treatment, DURAVYU, currently in Phase 3 development. Campbell brings over 30 years of ophthalmology commercial experience, including a key role in the launch of Lucentis. His appointment comes as EyePoint anticipates topline data from its Phase 3 program in wet AMD in mid-2026.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. reported its Q4 and full-year 2025 financial and operating results, highlighting a year of significant growth with total revenue up 38% to $1.4 billion and royalty revenue increasing 52% to $868 million. The company expanded its drug delivery portfolio through acquisitions of Hypercon and Surf Bio technologies, broadening its collaboration opportunities. Halozyme also discussed the strong performance of ENHANZE-enabled products like DARZALEX, PHESGO, and VYVGART Hytrulo, along with projections for continued revenue growth and strategic initiatives for long-term value creation into the 2040s.
EyePoint Appoints Michael Campbell as Chief Commercial Officer
EyePoint, Inc. has appointed Michael Campbell as its Chief Commercial Officer, a seasoned executive with over 30 years of leadership in retinal disease. Campbell will oversee the commercial strategy and launch readiness for DURAVYU, EyePoint's leading product candidate in Phase 3 development for wet AMD and DME. His extensive experience, including successful launches of prominent ophthalmology franchises like Lucentis and Xiidra, is expected to be instrumental in positioning DURAVYU for market success.
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade
UBS has upgraded Viatris Inc. (VTRS) to Buy from Neutral, raising its price target to $18, citing stronger growth prospects, a new product pipeline, continuous cost-cutting, rising profits, and efficient capital allocation. The company recently launched Inpefa in the UAE, the first market outside the U.S., with additional global launches planned. Viatris is expected to discuss its global rollout strategy during its Q4 and full-year 2025 results release on February 26, 2026, ahead of an Investor Event on March 19, 2026.
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade
UBS has upgraded Viatris Inc. (VTRS) to Buy from Neutral, raising its price target to $18 from $11, driven by efficient capital allocation, rising profits, and a strong new product pipeline. The company recently launched Inpefa in the UAE, the first market outside the U.S., with further global rollouts planned. Viatris is expected to focus on this global expansion as it prepares to release its Q4 and full-year 2025 results and host an Investor Event in March 2026.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During volatile market conditions, dividend-yielding healthcare stocks like UnitedHealth Group, Viatris, and CVS Health can be attractive to investors due to their high free cash flows and regular payouts. This article highlights the ratings and price targets from top-performing analysts for these three companies. Analysts from Mizuho, Truist Securities, Piper Sandler, Barclays, B of A Securities, and JP Morgan have provided recent evaluations and price targets for these stocks, which each offer a dividend yield over 3%.
New antibody from Teva and Sanofi keeps bowel disease at bay for 44 weeks
Teva and Sanofi announced positive Phase 2b results for investigational duvakitug, showing durable efficacy for 44 weeks in patients with ulcerative colitis (UC) and Crohn’s disease (CD). The drug maintained clinical remission of 58% (900 mg) and 47% (450 mg) in UC, and endoscopic response of 55% (900 mg) and 41% (450 mg) in CD. These results support ongoing Phase 3 programs, reinforcing duvakitug's potential as a leading TL1A therapy for inflammatory bowel disease.
Is State Street SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
The article evaluates the State Street SPDR Portfolio S&P 500 High Dividend ETF (SPYD), highlighting it as a smart beta ETF focused on large-cap value with a high dividend yield. It details the fund's objective to track the S&P 500 High Dividend Index, its low expense ratio of 0.07%, and its sector allocations, including top holdings like CVS Health Corp. The report concludes that SPYD is a strong option for investors seeking to outperform the Style Box - Large Cap Value segment, offering diversified exposure and solid performance.
(VTRS) and the Role of Price-Sensitive Allocations
This article provides an analysis of Viatris Inc. (NASDAQ: VTRS), highlighting strong sentiment across all horizons supporting an overweight bias despite elevated downside risk due to a lack of additional long-term support signals. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis and access to AI-generated real-time trading signals.
How Do Investors Really Feel About Viatris Inc?
Viatris Inc.'s short interest has increased by 10.36% since its last report, now standing at 27.83 million shares, which represents 2.77% of its tradable shares. This rise in short interest suggests a more bearish sentiment among investors, although the company's short interest is still lower than its peer group average of 3.58%. It would take traders 3.87 days on average to cover their short positions.
Where is Viatris Inc. (VTRS) headed according to the Street?
The provided article content was "MSN", which is insufficient to generate a summary or extract meaningful information about Viatris Inc. (VTRS). The article content is effectively empty.
Is Viatris (VTRS) Quietly Repositioning Its Deal-Making Strategy With a New Chief Legal Officer?
Viatris recently appointed Matthew J. Maletta as Chief Legal Officer, effective February 9, 2026, signaling a potential reinforcement of its legal capabilities for complex transactions and regulatory matters. This leadership change occurs as Viatris continues to navigate its investment narrative focused on converting its diversified generics and branded platform into improving cash flow, despite ongoing regulatory scrutiny and price pressures. The company's future hinges on its ability to manage regulatory issues and successfully launch differentiated products like Inpefa, which could impact analyst forecasts and the stock's fair value.
Is Viatris (VTRS) Quietly Repositioning Its Deal-Making Strategy With a New Chief Legal Officer?
Viatris (VTRS) recently appointed Matthew J. Maletta as Chief Legal Officer, effective February 9, 2026, signaling a potential reinforcement of its legal capabilities for complex corporate transactions and regulatory matters. Maletta's extensive pharmaceutical legal experience across generics and branded drugs could influence Viatris's investment narrative and risk profile. This strategic hire comes as Viatris continues to focus on broadening its higher-value cardiovascular portfolio and addressing ongoing regulatory issues.
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Navigating a 37.70% Potential Upside in Biotechnology
Theravance Biopharma, Inc. (TBPH) offers a compelling investment opportunity in the biotechnology sector, identified by a potential upside of 37.70% according to analyst targets. The company, known for its COPD medication YUPELRI and pipeline product Ampreloxetine, demonstrates strong revenue growth of 18.50% and a positive outlook from analysts. With its stock trading above moving averages and a reasonable forward P/E ratio, TBPH is positioned for future growth through innovation and strategic partnerships.
Viatris stock hits 52-week high at $15.61 By Investing.com
Viatris (VTRS) stock has reached a 52-week high of $15.61, reflecting a 53.96% return over the past 12 months and a 64.12% surge in the last six months. InvestingPro analysis suggests the stock is undervalued with a 3.08% dividend yield. Recent company developments include a raised price target from Piper Sandler, a new Chief People and Corporate Affairs Officer, and four regulatory milestones, including an FDA approval for a generic injectable medication.
Viatris stock hits 52-week high at $15.61 By Investing.com
Viatris Inc (VTRS) stock has reached a 52-week high of $15.61, reflecting a significant recovery with returns of 53.96% over the past year and 64.12% in the last six months. InvestingPro analysis suggests the stock is currently undervalued and offers a 3.08% dividend yield. The company has also seen positive developments, including an increased price target from Piper Sandler, a new Chief People and Corporate Affairs Officer, and four regulatory milestones, including an FDA approval for a generic injectable medication.
Viatris Inc. stock rises Tuesday, outperforms market
Viatris Inc. (VTRS) stock increased by 2.51% to $15.95 on Tuesday, marking its third consecutive day of gains. This rise occurred during a mixed trading session where the Dow Jones Industrial Average (DJIA) saw a slight increase, while the S&P 500 Index (SPX) experienced a decline. The company's performance outperformed the overall market trends for the day.
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse
Viatris Inc. (NASDAQ: VTRS) has completed its "Phase 1" divestiture program and is transitioning from a generic drug conglomerate to a focused specialty pharmaceutical company, particularly in ophthalmology. Despite initial skepticism and historical debt, aggressive restructuring and a disciplined capital allocation strategy have led Wall Street to re-evaluate the company. With consistent free cash flow, significant debt reduction, and a new leadership team, Viatris aims for growth through innovation in specialty areas, although it faces risks from regulatory scrutiny and generic erosion.
Viatris stock hits 52-week high at $15.61
Viatris Inc. (VTRS) stock has reached a 52-week high of $15.61, reflecting significant growth and investor confidence with returns of 53.96% in 12 months and 64.12% in six months. InvestingPro analysis suggests the stock is undervalued and offers a 3.08% dividend yield. Recent company developments include a raised price target from Piper Sandler, a new Chief People and Corporate Affairs Officer, multiple regulatory milestones including an FDA approval, and the annual shareholders' meeting which approved director nominees and auditor appointments.
Where is Viatris Inc. (VTRS) Headed According to the Street?
Viatris Inc. (VTRS) recently received a price target update from Piper Sandler to $12, maintaining a Neutral rating, citing strength in its brand business and new product launches. The company also launched Inpefa® (sotagliflozin) in the UAE, marking an expansion of this heart failure treatment outside of Europe and the U.S. Viatris, a global healthcare company, plans further international launches of Inpefa, which is the first and only dual SGLT1/2 inhibitor approved for heart failure treatment.
Viatris Septerna BIO Takeda name new legal chiefs
Viatris, Septerna Inc., the Biotechnology Innovation Organization (BIO), and Takeda have announced new legal leadership appointments. Matthew J. Maletta will become CLO at Viatris, Mark A. Wilson will join Septerna as CLO, Joe Franklin, JD, PhD, is the new chief legal and policy officer for BIO, and Natalie Furney will join Takeda's executive team for its Global Legal, Ethics & Compliance unit. These appointments reflect a reshuffling of legal leadership across the pharmaceutical and biotechnology sectors.
Viatris Septerna BIO Takeda name new legal chiefs
Viatris, Septerna, BIO, and Takeda have announced new legal leadership appointments, signaling significant changes across the pharmaceutical and biotechnology sectors. Matthew J. Maletta joins Viatris as CLO, Mark A. Wilson is appointed CLO at Septerna, Joe Franklin becomes Chief Legal and Policy Officer at BIO, and Natalie Furney joins Takeda's executive team for Global Legal, Ethics & Compliance. These strategic hires aim to bolster legal, compliance, and policy functions within these organizations.
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS)
Two analysts have issued bullish sentiments on healthcare companies Boston Scientific (BSX) and Viatris (VTRS). A Bank of America Securities analyst maintained a Buy rating on Boston Scientific with a $105 price target, and the consensus for BSX is a Strong Buy with a 40.0% upside. Viatris has a Moderate Buy consensus with a target of $13.60, based on insights from a 4-star analyst.
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS)
Two healthcare companies, Boston Scientific (BSX) and Viatris (VTRS), have received bullish sentiments from analysts. Boston Scientific was rated a "Buy" with a target of $105.00 by Bank of America Securities, with a consensus price target of $108.14. Viatris has a "Moderate Buy" consensus with a price target of $13.60.
Viatris stock hits 52-week high at $15.61
Viatris Inc. (VTRS) stock has hit a 52-week high of $15.61, reflecting strong market performance with a 53.96% return over the past year. InvestingPro analysis indicates the stock is undervalued with a 3.08% dividend yield, and recent positive developments include increased price targets, a new executive appointment, and multiple regulatory approvals for generic medications.
Where is Viatris Inc. (VTRS) Headed According to the Street?
Viatris Inc. (VTRS) is considered one of the best healthcare stocks under $50, with Piper Sandler recently adjusting its price target to $12 while maintaining a Neutral rating. The company launched Inpefa® (sotagliflozin) in the UAE, marking an expansion into new markets and supporting its strategy for broader access to new products. Viatris is a global healthcare company specializing in various therapeutic areas and is working to grow its brand business across different geographies.
Viatris Stock Hits 52-Week High After UBS Buy Rating & $18 Price Target | Market Update 2026 - News and Statistics
Viatris stock rose 6.4% and reached a new 52-week high of $15.55 after UBS upgraded its rating from Neutral to Buy and increased its price target to $18. This upgrade suggests a more positive outlook for the company's prospects. Despite a significant drop in the past year due to disappointing Q4 results and weak guidance, Viatris shares have climbed 24.8% since the beginning of the year.
Why Viatris (VTRS) Stock Is Up Today
Shares of medication company Viatris (VTRS) jumped 6.4% after UBS upgraded the stock from "Neutral" to "Buy" and increased its price target to $18 from $11. This upgrade suggests a positive outlook for the company despite a previously weak fourth-quarter performance and disappointing 2025 guidance due to regulatory challenges. Viatris is up 24.8% year-to-date and has reached a new 52-week high.
Viatris gains as UBS upgrades to Buy (VTRS:NASDAQ)
Viatris (VTRS) shares rose after UBS upgraded the stock to Buy from Neutral, increasing its price target to $11 from $8. The upgrade is based on a promising growth outlook and an expanding drug pipeline for the company.
US drugmaker Viatris appoints in-house pharma veteran as next CLO
Viatris, a US pharmaceutical company, has appointed Matthew Maletta as its new Chief Legal Officer, replacing Brian Romano who is departing after more than two decades. Maletta, an in-house pharma veteran with nearly 30 years of public company legal experience, was previously CLO at Par Health and Endo, and spent over a decade at Allergan. He is expected to contribute significantly to Viatris's transformation and growth strategy.
Azenta stock hits 52-week high at $28.44 despite yearly decline
Azenta Inc. stock recently reached a 52-week high of $28.44, yet it has experienced a 45.11% decline over the past year. Despite being in oversold territory and trading below its Fair Value with a strong balance sheet, the company reported a miss on EPS forecasts but exceeded revenue expectations in its first-quarter 2026 earnings. Analysts have adjusted price targets due to lower gross margins, highlighting the stock's volatility for investors.
Viatris Inc. stock rises Monday, outperforms market
Viatris Inc. stock (VTRS) saw a significant rise of 6.72% on Monday, closing at $15.56. This performance outpaced the broader market, which also experienced gains, with the S&P 500 Index and Dow Jones Industrial Average both increasing. This marks the second consecutive day of gains for Viatris.
Why Viatris (VTRS) Stock Is Up Today
Viatris (VTRS) stock surged 6.4% after UBS upgraded it from "Neutral" to "Buy" and raised its price target from $11 to $18, signaling significant potential upside. This positive re-evaluation by an investment bank often indicates a more favorable outlook on the company's future performance. Despite past volatility and a challenging Q4 earnings report last year, Viatris has seen a 24.8% increase since the beginning of the year, reaching a new 52-week high.
JBTMarel Corp stock hits 52-week high at 169.97 USD
JBTMarel Corp's stock has reached a new 52-week high of $169.97 USD, representing a 31.77% appreciation over the past year. Despite not being profitable in the last twelve months, analysts expect the company to return to profitability this year with a forecasted EPS of $6.32 USD. The company also announced a quarterly cash dividend of $0.10 per share and received an upgrade from Jefferies from Hold to Buy, with a price target increase from $150.00 to $180.00, driven by expected earnings growth and recovery in food processing demand.
Jazz Pharmaceuticals (JAZZ) Valuation After HERIZON GEA Trial Upside And Planned 2026 sBLA Filing
Jazz Pharmaceuticals is receiving positive attention following strong HERIZON GEA trial results and plans for a 2026 sBLA filing for gastroesophageal adenocarcinoma therapies, leading to significant share price returns over the past 90 days and one year. Despite a year-to-date share price decline, the company is considered 22.3% undervalued by analysts, with a fair value estimate of $213.00, driven by anticipated new therapy approvals and global expansion. Investors are advised to consider potential pipeline risks and patent expiries alongside the growth prospects.
How HERIZON-GEA’s First-Line GEA Data And sBLA Plan At Jazz Pharmaceuticals (JAZZ) Has Changed Its Investment Story
Jazz Pharmaceuticals recently announced positive data from its HERIZON-GEA trial and intends to submit a supplemental Biologics License Application for first-line gastroesophageal adenocarcinoma treatment in early 2026. This development significantly enhances the company's investment narrative by providing a clear near-term catalyst and broadening the potential market for its pipeline asset, zanidatamab. While addressing potential concerns regarding debt and execution risks, the news highlights the drug's practice-changing profile and its potential to influence broader investment perspectives.
Is Viatris’ New Deal-Tested CLO a Turning Point in Its Transformation Strategy (VTRS)?
Viatris Inc. has appointed Matthew J. Maletta as its new Chief Legal Officer, effective February 9, 2026, bringing his extensive M&A and legal experience to the company. While Maletta's background in complex transactions may influence Viatris's future portfolio decisions, this leadership change is seen as supportive rather than thesis-changing. Investors are focused on the upcoming Q4 2025 results and March investor event, which will provide more crucial insights into the company's financial health and transformation strategy.
Is Viatris’ New Deal-Tested CLO a Turning Point in Its Transformation Strategy (VTRS)?
Viatris Inc. has appointed Matthew J. Maletta as its new Chief Legal Officer, succeeding Brian Roman. Maletta's strong background in complex transactions and legal leadership across both generic and branded drug companies is seen as a supportive development for Viatris' ongoing operational transformation. While his appointment is incremental, it could influence future portfolio decisions, adding to the company's investment narrative focused on converting its large revenue base into cash generation despite past losses.
Is Corcept Therapeutics (CORT) Price Weakness Creating A Long Term Opportunity?
Corcept Therapeutics (CORT) has experienced significant share price volatility, with a 43.6% decline over the past year. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock could be undervalued by 88.3%, estimating an intrinsic value of $328.66 per share compared to its current price of $38.36. The company's P/E ratio also sits below Simply Wall St's proprietary Fair Ratio, further suggesting a potential discount.
Responsive Playbooks and the VTRS Inflection
This article analyzes Viatris Inc. (NASDAQ: VTRS), indicating strong sentiment across all horizons despite elevated downside risk and no clear price positioning signals. It presents three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis. The analysis suggests an overweight bias supported by robust sentiment signals.
LTC Properties stock hits 52-week high at 37.97 USD
LTC Properties Inc. (LTC) stock reached a 52-week high of $37.97, reflecting a 13.05% total return over the past year and showcasing strong investor confidence. The real estate investment trust, specializing in senior housing and healthcare properties, boasts a $1.75 billion market cap, a 6.22% dividend yield, and 25 years of consistent dividend payments. Recent activities include Q3 2025 financial results with a revenue beat, the acquisition of a $108 million senior housing portfolio, and an increase in its credit facility to $800 million.
STERIS (NYSE:STE) Beats Q4 CY2025 Sales Expectations
STERIS (NYSE:STE) reported Q4 CY2025 sales of $1.50 billion, exceeding Wall Street's revenue expectations by 1%, with a 9.2% year-on-year growth. The company's non-GAAP profit of $2.53 per share was in line with analyst estimates, and management reiterated its full-year Adjusted EPS guidance. Despite a slight deceleration in projected revenue growth, the company's long-term sales performance and operating margin growth indicate a strong market position.
